Iovance Biotherapeutics (NASDAQ:IOVA – Get Free Report) is expected to be posting its quarterly earnings results after the market closes on Thursday, February 27th. Analysts expect Iovance Biotherapeutics to post earnings of ($0.26) per share and revenue of $72.17 million for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.
Iovance Biotherapeutics Price Performance
Shares of IOVA opened at $5.34 on Wednesday. The firm’s 50 day simple moving average is $6.35 and its 200 day simple moving average is $8.66. The company has a market capitalization of $1.63 billion, a P/E ratio of -3.58 and a beta of 0.54. Iovance Biotherapeutics has a 1-year low of $5.05 and a 1-year high of $18.33.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $32.00 target price on shares of Iovance Biotherapeutics in a research note on Wednesday, November 6th. Piper Sandler lowered their target price on shares of Iovance Biotherapeutics from $10.00 to $7.50 and set a “neutral” rating on the stock in a research note on Friday, January 31st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, Iovance Biotherapeutics has an average rating of “Moderate Buy” and a consensus price target of $21.07.
About Iovance Biotherapeutics
Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.
Read More
- Five stocks we like better than Iovance Biotherapeutics
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- Nebius Slides Post-Earnings: A Long-Term Buy Opportunity?
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- NVIDIA Stock: A Market Barometer in Tech’s Turbulent Times
- What is a support level?
- Palantir Stock Nears Bear Market Territory – Why and What’s Next?
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
